Abstract 2201: The molecular signature of tumor cells that are sensitives to a new tight binder NAMPT inhibitor.
Sandrine Hilairet(Sanofi (France)), Monsif Bouaboula(Sanofi (United States)), François Autelitano(Evotec (Germany)), Annick Péleraux(Sanofi (France)), Christoph Lengauer(Blueprint Medicines (United States)), Maysoun Shomali(Sanofi (United States)), Paul R. August(Center for Discovery), Marion Dorsh, Jack Pollard(Sanofi (United States)), Jérôme Arigon(Sanofi (France)), Samir Jegham(Sanofi (France)), Rosalía Arrebola(Sanofi (France)), Sylvie Cosnier(Sanofi (France)), Omar Jbilo(Sanofi (France)), Regine Floutard(Sanofi (France)), Stephan Reiling, Frederico Nardi(Sanofi (France)), Jason A. Sager, Francisco Adrián(HiFiBiO Therapeutics (United States)), Carlos Garcı́a-Echeverrı́a(Novartis Institutes for BioMedical Research)
Cited by 0
Related Papers
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
|Nature Medicine|2008|1.3k
Is a p53-Regulated Inhibitor of G2/M Progression
|Molecular Cell|1997|1.2k
Glucose Deprivation Contributes to the Development of <i>KRAS</i> Pathway Mutations in Tumor Cells
|Science|2009|908
Somatic mutations of the mitochondrial genome in human colorectal tumours
|Nature Genetics|1998|839
Contribution of bone marrow–derived endothelial cells to human tumor vasculature
|Nature Medicine|2005|480